Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer globally. Even with multimodality treatment, including surgery, radiation, and chemotherapy, the 5-year survival rate remains at 60%.
Although epidermal growth factor receptor (EGFR) is frequently overexpressed in head and neck cancers, EGFR inhibitors have not been as effective as anticipated in the clinic, suggesting that other cellular pathways are...
